Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Primary care is the backbone of CKM syndrome management. A new expert perspective argues that while nephrology and cardiology debate ownership of cardiovascular-kidney-metabolic (CKM) syndrome, primary care must anchor early detection, treatment, and coordinated follow-up. The recently launched HHS Kidney Care National Plan adds fresh urgency to close the gaps in fragmented care.
Cardiovascular-kidney-metabolic (CKM) syndrome sits at the intersection of heart disease, kidney disease, and metabolic conditions — yet the U.S. healthcare system has long treated these separately. A new expert perspective argues that primary care must be the cornerstone of CKM management, supported by a clearly coordinated multidisciplinary team. The October 2026 launch of the HHS Kidney Care National Plan adds federal momentum to this call for earlier detection and prevention.
While the Kidney Health Evaluation for Patients with Diabetes (KED) measure has improved accountability for annual kidney testing, the author emphasizes that completing a test is just the beginning — results must lead to interpretation, communication, and timely treatment. Evidence-backed therapies like ACE inhibitors, ARBs, and SGLT2 inhibitors can slow kidney disease progression and reduce cardiorenal complications, but primary care clinicians need better education to translate detection into action.
Key Takeaways:
Why it matters: CKM syndrome affects millions, and fragmented care leads to avoidable complications and costs. Anchoring management in primary care — with clear team roles and accountability — could meaningfully improve outcomes and quality of life for high-risk patients.